Terms: = Ovarian cancer AND CHD4, Mi2-BETA, 1108, ENSG00000111642, Mi-2b, DKFZp686E06161, Q14839 AND Prognosis
4 results:
1. The epigenetic factor chd4 contributes to metastasis by regulating the EZH2/β-catenin axis and acts as a therapeutic target in ovarian cancer.
Wang J; Zhong F; Li J; Yue H; Li W; Lu X
J Transl Med; 2023 Jan; 21(1):38. PubMed ID: 36681835
[TBL] [Abstract] [Full Text] [Related]
2. Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.
García-Sanz P; Triviño JC; Mota A; Pérez López M; Colás E; Rojo-Sebastián A; García Á; Gatius S; Ruiz M; Prat J; López-López R; Abal M; Gil-Moreno A; Reventós J; Matias-Guiu X; Moreno-Bueno G
Int J Cancer; 2017 Apr; 140(7):1551-1563. PubMed ID: 27997699
[TBL] [Abstract] [Full Text] [Related]
3. High Expression of miR-532-5p, a Tumor Suppressor, Leads to Better prognosis in ovarian cancer Both In Vivo and In Vitro.
Wang F; Chang JT; Kao CJ; Huang RS
Mol Cancer Ther; 2016 May; 15(5):1123-31. PubMed ID: 26873729
[TBL] [Abstract] [Full Text] [Related]
4. [Relationship between hormone therapy in women with ovarian malignancy and prognosis].
Li L; Pan ZM; Chen XQ; Gao K; Zhang W; Luo Y; Yao ZQ; Liang XQ; Huang W; Yao DS
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):843-8. PubMed ID: 19087569
[TBL] [Abstract] [Full Text] [Related]
